Clinical Trial Update: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating initial therapy with encorafenib and binimetinib followed by cemiplimab and fianlimab in patients with BRAF-mutant melanoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• Fianlimab (fianlimab)
• Libtayo (cemiplimab)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: Grupo Español Multidisciplinar de Melanoma | Conditions: Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases | Phase 2 | Status: RECRUITING